Moving From the Clinic to the C-suite with OcuTerra’s Dr. David Tanzer and Dr. Kerrie Brady

PODCAST EPISODE 307

Click here to watch the video version of this podcast.

OIS podcast host Paul Karpecki, OD, FAAO, caught up with OcuTerra Therapeutics CEO Kerrie Brady, PharmD, and CMO David Tanzer, MD, to discuss OcuTerra’s novel small-molecule integrin inhibitor. Preclinical data impressed Dr. Tanzer enough to resign from his CMO role at Novartis to help develop OTT166, a topical agent for moderately severe to severe nonproliferative diabetic retinopathy (DR).

The standard of care for patients with DR is to simply watch and wait. Intravitreal anti-VEGF injections are an option when complications occur, but they can pose a significant treatment burden for patients. Phase I data for OTT166 looks promising, and patients can administer the drops at home.

With $35 million in Series B financing secured, OcuTerra will move into Phase II clinical trials early next year, with the goal of dosing 200 patients for the study.

Listen to the podcast today to hear Dr. Brady and Dr. Tanzer take a deep dive into the mechanism of action of OTT166 and the objectives for the Phase II study. You’ll also discover:
• The science behind the fluorination technology that enables OTT166.
• The story of how both transitioned from medicine to industry. Dr. Brady entered pharma and biotech after completing a PharmD program. Today she’s an “unrepentant entrepreneur.” Dr. Tanzer practiced ophthalmology for 20 years before moving into executive roles at Abbott Medical Optics—since acquired by Johnson & Johnson Vision—Novartis, and now OcuTerra.
• Dr. Tanzer’s advice for physicians with industry aspirations, and Dr. Brady’s advice for aspiring entrepreneurs.

Click “play” to listen.

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.

Meet Our Hosts

Ehsan Sadri
ehsan sadri
Firas Rahhal
Firas Rahhal, MD
Paul Karpecki
Paul Karpecki
Robert Rothman
Robert Rothman
Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.